Alzheimer's drug ALZ-801 tested Long-Term in High-Risk group
NCT ID NCT06304883
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the long-term safety and effects of ALZ-801, a tablet taken twice daily, in 163 people with early Alzheimer's disease who have the APOE4/4 gene. Participants had already completed a previous phase 3 study. The goal was to see if the drug could slow cognitive decline and brain shrinkage over two years. However, the study was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALZ-801 (a tablet taken twice a day)
What this could lead to
If it works, this could point toward a treatment that slows cognitive decline and brain shrinkage in people with early Alzheimer's who have the APOE4/4 gene.
What could go wrong
This trial was terminated early, so results may be incomplete. It is an open-label extension, meaning everyone knows they are getting the drug, which can bias results. The drug may not show clear benefits or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ALZ Research and Treatment Center (A.R.T.C.)
Stuart, Florida, 34997, United States
-
ALZ Research and Treatment Center (A.R.T.C.)
Wellington, Florida, 33414, United States
-
AMC Research
Matthews, North Carolina, 28105, United States
-
ATP Clinical Research
Costa Mesa, California, 92626, United States
-
Abington Neurological Associates
Abington, Pennsylvania, 19001, United States
-
Advanced Memory Research Center
Toms River, New Jersey, 08755, United States
-
Aqualane Clinical Research
Naples, Florida, 34105, United States
-
Banner Sun Health Research Institute
Sun City, Arizona, 85351, United States
-
Center for Cognitive Health
Portland, Oregon, 97225, United States
-
Centricity Research
Halifax, Nova Scotia, B3S 1N2, Canada
-
Charter Research
Orlando, Florida, 32803, United States
-
Columbus Memory Center
Columbus, Georgia, 31909, United States
-
Fort Wayne Neurological Center
Fort Wayne, Indiana, 46804, United States
-
Headlands Research Eastern MA
Plymouth, Massachusetts, 02360, United States
-
JEM Research Institute, Headlands Site
Atlantis, Florida, 33462, United States
-
K2 Medical Research, LLC
Maitland, Florida, 32751, United States
-
Kawartha Centre - Redefining Healthy Aging
Peterborough, Ontario, K9H 2P4, Canada
-
Mount Sinai Medical Center
Miami Beach, Florida, 33140, United States
-
NYU Alzheimer's Disease Research Center
New York, New York, 10016, United States
-
NeuroClin Glasgow Ltd
Motherwell, North Lanarkshire, ML1 4UF, United Kingdom
-
Neurological Associates of Albany
Albany, New York, 12208, United States
-
Northwest Clinical Research Center
Bellevue, Washington, 98007, United States
-
OCT Research ULC (dba Okanagan Clinical Trials)
Kelowna, British Columbia, V1Y 1Z9, Canada
-
Premiere Research Institute
West Palm Beach, Florida, 33407, United States
-
Progressive Medical Research
Port Orange, Florida, 32127, United States
-
Re-Cognition Health Ltd Birmingham
Birmingham, West Midlands, B16 8LT, United Kingdom
-
Re-Cognition Health Ltd Bristol
Bristol, BS32 4SY, United Kingdom
-
Re-Cognition Health Ltd Guildford
Guildford, Surrey, GU2 7YD, United Kingdom
-
Re-Cognition Health Ltd London
London, Greater London, W1G 9JF, United Kingdom
-
Re-Cognition Health Ltd Plymouth
Plymouth, Devon, PL6 8BT, United Kingdom
-
Re-Cognition Health Ltd Winchester
Winchester, SO21 1HU, United Kingdom
-
Re:Cognition Health
Fairfax, Virginia, 22031, United States
-
Recherches Neuro-Hippocampe Inc., d/b/a Ottawa Memory Clinic
Ottawa, Ontario, K1Z 1G3, Canada
-
Rhode Island Mood & Memory Research Institute
East Providence, Rhode Island, 02914, United States
-
Sutter Health
Sacramento, California, 95816, United States
-
Toronto Memory Program
Toronto, Ontario, M3B 2S7, Canada
-
Torrance Clinical Research Institute
Lomita, California, 90717, United States
-
Triad Clinical Trials
Greensboro, North Carolina, 27410, United States
-
UT Health Science Center at Houston
Houston, Texas, 77054, United States
-
University of Rochester Medical Center
Rochester, New York, 14620, United States
-
Xenoscience, Inc.
Phoenix, Arizona, 85004, United States